Retatrutide activates GLP-1 receptors (insulin secretion, appetite suppression), GIP receptors (insulin secretion, adipose tissue modulation), and glucagon receptors (increased energy expenditure, hepatic glucose regulation) concurrently
For example, the -adrenergic receptor antagonist propranolol inhibited dopamine-induced increases in nuclear factor kappa-light-chain-enhancer of activated B-cells (NF- B), interleukin (IL)-6, and IL-8 and blocked dopamine-mediated IL-12p40 suppression in human keratinocytes and rodent macrophages (Hasko et al., 2002
Although glucagon typically raises blood sugar, in the presence of GLP-1 and GIP, the response becomes more balanced, leading to: increased energy expenditure enhanced fat oxidation greater metabolic burn at rest reduction in liver fat prevention of metabolic slowdown during weight loss This combination makes retatrutide particularly effective for individuals who typically plateau on GLP-1 drugs due to metabolic adaptation
252 WangS.LongH.HouL.FengB.MaZ.WuY.et al (2023)
That doesn't mean there can't be a lawsuit
